Novo NordiskNVO

British regulators have authorized Foundayo, a weight-loss and diabetes pill from Eli Lilly. This is the first time a European country has approved this specific pill, which competes directly with Novo Nordisk's injectable drugs like Wegovy and Ozempic.

While Novo Nordisk currently dominates the market, a pill is often easier for patients to take and simpler for companies to ship than injections. This approval marks a new phase of competition in Europe. It puts pressure on Novo Nordisk to speed up its own work on oral versions of its medicines to keep its lead in the region.

Source: Reuters

Profit and sales beat expectations despite stock drop

While Novo Nordisk was the first to market with its blockbuster weight-loss drugs, Eli Lilly has moved quickly with its own competing treatments. Analysts are increasingly focused on how Lilly has managed to capture a large share of the market by moving faster on production and clinical data.

This competition matters because it could lead to price wars, where both companies lower prices to win over insurers and patients. If Novo cannot maintain its edge through better manufacturing or new drug versions, it may see its high profit margins start to shrink. It is no longer the only major player in a massive market, and staying ahead will require heavy spending on new factories and research.

Source: Market Watch

Following a few disappointing updates regarding its future drugs, some thought the company might buy a large rival to jumpstart its growth. The CEO has now clarified that he is only interested in smaller deals that add specific technologies or products, known as bolt-on acquisitions, rather than a transformative merger that could be risky and distracting.

This approach shows management is confident in its own labs despite recent trial failures. While it means the company won't have a sudden, massive boost from a merger, it also avoids the debt and integration headaches that come with giant deals. For now, the focus remains on fixing its own production and drug development.

Source: WSJ

The company won a preliminary injunction, which is a temporary court order to stop an action, against a Dutch firm selling a version of semaglutide as a nasal spray. Novo Nordisk argued this infringed on its patents, the legal protections that prevent others from copying its inventions. This is a small but helpful win in the company's broader effort to protect its most profitable drugs from unapproved versions. While one pharmacy in the Netherlands doesn't change the global picture, it sets a precedent that Novo will aggressively defend its territory against companies trying to sell alternative versions of Wegovy and Ozempic.

Source: Reuters